The Translational Cancer Biology Training Program
University of Massachusetts Medical School
Program Director: Arthur M. Mercurio, Ph.D.
The Translational Cancer Biology Training Program at the University of Massachusetts Medical School (www.umassmed.edu) is an NIH-funded training grant (T32) that supports post-doctoral and pre-doctoral trainees who are committed to careers in cancer research. The program is based in the Department of Cancer Biology but it includes faculty from multiple basic science and clinical departments, T32 Faculty. Faculty are selected for participation in this program based on their scientific achievements and track record of funding in cancer research, appreciation for translational cancer research and their experience in mentoring trainees.
The key strengths of the program are cancer cell biology and cancer genetics. A major intent of this inter-departmental program is to provide the trainees, most of whom are basic scientists, with an appreciation for translational cancer research and with an ability to interact effectively with clinicians that will influence and guide their careers. In addition to their laboratory training, all trainees are encouraged to participate in:
Disease-based conferences (Breast Cancer, GI Cancer, GU Cancer, Leukemia and Lymphoma) that bring together cancer clinicians and basic scientists. These conferences enable trainees to explore the clinical ramifications of their research and develop an appreciation for translational research.
The Cancer Biology Data Club, a forum that enables trainees to present their research to faculty and other trainees.
Pre-Doctoral Trainees interested in the program should contact the Graduate School of Biomedical Sciences for admission to the Cancer Biology Program.
Post-Doctoral Trainees interested in the program should contact either individual faculty members, T32 Faculty or the Program Director, Arthur M. Mercurio, Ph.D.
About the University of Massachusetts Medical School: The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $176 million in research funding annually, 80 percent of which comes from federal funding sources. The work of UMMS researcher Craig Mello, PhD, an investigator of the prestigious Howard Hughes Medical Institute (HHMI), and his colleague Andrew Fire, PhD, then of the Carnegie Institution of Washington, toward the discovery of RNA interference was awarded the 2006 Nobel Prize in Physiology or Medicine, hailed as the "Breakthrough of the Year" in 2002 by Science magazine and has spawned a new and promising field of research, the global impact of which may prove astounding. UMMS is the academic partner of UMass Memorial Health Care, the largest health care provider in Central Massachusetts. For more information, visit www.umassmed.edu.